Compartir
array:24 [ "pii" => "S0210480609741130" "issn" => "02104806" "doi" => "10.1016/S0210-4806(09)74113-0" "estado" => "S300" "fechaPublicacion" => "2009-01-01" "aid" => "74113" "copyright" => "Asociación Española de Urología (AEU)" "copyrightAnyo" => "2009" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:138-42" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1695 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 1033 "PDF" => 655 ] ] "itemSiguiente" => array:18 [ "pii" => "S0210480609741142" "issn" => "02104806" "doi" => "10.1016/S0210-4806(09)74114-2" "estado" => "S300" "fechaPublicacion" => "2009-01-01" "aid" => "74114" "copyright" => "Asociación Española de Urología (AEU)" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:143-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1943 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 1073 "PDF" => 862 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Cáncer de pene. Nuestra experiencia en 15 años" "tienePdf" => array:2 [ 0 => "es" 1 => "en" ] "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "143" "paginaFinal" => "148" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Cancer of the penis. Our experience in 15 years" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:2 [ "es" => true "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Di Capua Sacoto, Sátur Lujan Marco, Gonzalo Morales Solchaga, Alberto Budía Alba, L. José Pontones Moreno, F. Juan Cruz Jiménez" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Carlos" "apellidos" => "Di Capua Sacoto" ] 1 => array:2 [ "nombre" => "Sátur" "apellidos" => "Lujan Marco" ] 2 => array:2 [ "nombre" => "Gonzalo" "apellidos" => "Morales Solchaga" ] 3 => array:2 [ "nombre" => "Alberto" "apellidos" => "Budía Alba" ] 4 => array:2 [ "nombre" => "L." "apellidos" => "José Pontones Moreno" ] 5 => array:2 [ "nombre" => "F." "apellidos" => "Juan Cruz Jiménez" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480609741142?idApp=UINPBA00004N" "url" => "/02104806/0000003300000002/v1_201304251922/S0210480609741142/v1_201304251922/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0210480609741129" "issn" => "02104806" "doi" => "10.1016/S0210-4806(09)74112-9" "estado" => "S300" "fechaPublicacion" => "2009-01-01" "aid" => "74112" "copyright" => "Asociación Española de Urología (AEU)" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:134-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1802 "formatos" => array:3 [ "EPUB" => 5 "HTML" => 946 "PDF" => 851 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Dolor durante biopsia de próstata guiada por ultrasonografía transrectal: Comparación del uso o no de Xilocaína gel como anestésico local" "tienePdf" => array:2 [ 0 => "es" 1 => "en" ] "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "134" "paginaFinal" => "137" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Pain during transrectal ultrasound guided needle biopsy Of the prostate : comparison of the use or not of lidocaine Gel" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:2 [ "es" => true "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gilmer A. Díaz Pérez, Luis Meza Montoya, Carlos Morante Deza, Mariela Pow-Sang Godoy, Víctor Destefano Urrutia" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Gilmer" "apellidos" => "A. Díaz Pérez" ] 1 => array:2 [ "nombre" => "Luis" "apellidos" => "Meza Montoya" ] 2 => array:2 [ "nombre" => "Carlos" "apellidos" => "Morante Deza" ] 3 => array:2 [ "nombre" => "Mariela" "apellidos" => "Pow-Sang Godoy" ] 4 => array:2 [ "nombre" => "Víctor" "apellidos" => "Destefano Urrutia" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480609741129?idApp=UINPBA00004N" "url" => "/02104806/0000003300000002/v1_201304251922/S0210480609741129/v1_201304251922/es/main.assets" ] "es" => array:14 [ "idiomaDefecto" => true "titulo" => "Nuevas dianas terapéuticas para el carcinoma de células renales metastásico. Resultados del tratamiento con bevacizumab en monoterapia en un único centro hospitalario" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "138" "paginaFinal" => "142" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Verónica Calderero Aragón, Roberto Pazo Cid, Teresa Puértolas Hernández, Angel Artal Cortés, Angel Borque Fernando, Mª Jesús Gil Sanz" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Verónica" "apellidos" => "Calderero Aragón" "email" => array:1 [ 0 => "dracalde@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "cor0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff0005" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] 1 => array:3 [ "nombre" => "Roberto" "apellidos" => "Pazo Cid" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Teresa" "apellidos" => "Puértolas Hernández" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Angel" "apellidos" => "Artal Cortés" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "Angel" "apellidos" => "Borque Fernando" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] 5 => array:3 [ "nombre" => "Mª" "apellidos" => "Jesús Gil Sanz" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Oncología Médica. Hospital Universitario Miguel Servet. Zaragoza, España" "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Urología. Hospital Universitario Miguel Servet. Zaragoza, España" "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Oncología Médica. Servicio de Urología. Hospital Universitario Miguel Servet. Zaragoza, España" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "1" "correspondencia" => "Correspondencia autor: Dra. Verónica Calderero Aragón Servicio de Oncología Médica. Hospital Universitario Miguel Servet Pº Isabel La Católica, 1-3 - 50009 Zaragoza Tel.: 976 765 500" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Novel therapeutic targets in metastatic renal cell carcinoma. Results of the treatment with single-agent bevacizumab in a single institution" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2008-08-31" "fechaAceptado" => "2008-10-31" "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec88851" "palabras" => array:3 [ 0 => "Bevacizumab" 1 => "Carcinoma renal" 2 => "Nuevos agentes" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec88852" "palabras" => array:3 [ 0 => "Bevacizumab" 1 => "Renal cell carcinoma" 2 => "Novel agents" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Objetivos</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">En la última década se están desarrollando multitud de nuevas moléculas que ofrecen resultados esperanzadores para el tratamiento del CCR metastásico. Este estudio describe nuestra experiencia en 25 pacientes tratados con bevacizumab en monoterapia.</p> <span class="elsevierStyleSectionTitle">Material y métodos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se analizan los resultados obtenidos en 25 pacientes con CCR metastásico tratados con Bevacizumab (10 mg/Kg quincenal) entre enero del 2006 y enero del 2008. Se recogieron datos acerca del tipo de cirugía practicada, tipo histológico, estadio tumoral, grupo de riesgo de Motzer, localizaciones metastásicas, número de ciclos administrados, tiempo hasta la progresión y supervivencia global.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Se analizaron 25 pacientes (16 varones y 9 mujeres), con una mediana de edad de 59 años. Más de la mitad de ellos (19) se había sometido a algún tipo de intervención quirúrgica (14 nefrectomía radical, 4 citorreductora y 1 tumorectomía). La mayor parte de los enfermos presentaban histología de células claras (22). 14 pacientes pertenecían al grupo de buen pronóstico de Motzer, 8 al grupo de pronóstico intermedio y 3 al de mal pronóstico. La mediana de tiempo hasta la progresión fue de 19 semanas, con una mediana de supervivencia global desde el inicio de tratamiento de 8,7 meses.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El bevacizumab en monoterapia ofrece unos resultados modestos para el tratamiento del CCR metastásico. Su reciente aprobación en combinación con Interferon, y la aparición progresiva de distintas dianas terapéuticas, permitirá optimizar los resultados en los próximos años.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Aim</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Along the past decade a number of new agents have been developed showing promising results in the treatment of metastatic renal cell carcinoma. We describe our experience with the use of bevacizumab in monotherapy in the Urology and Medical Oncology departments of our institution.</p> <span class="elsevierStyleSectionTitle">Material and methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A consecutive series of patients treated with Bevacizumab 10 mg/Kg every 14 days between January 2006 and January 2008 has been assessed. Data concerning the type of surgery, histological subtype, tumor stage, Motzer’s risk group, metastatic sites number of bevacizumab courses given, time to progression and overall survival were collected.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">25 patients (16 male, 9 female) were analyzed. Median age was 59 years. Nineteen of them (75%) had prior surgery: radical nephrectomy 14, cytoreductive 4 y tumorectomy 1). Clear cell carcinoma was the most frequent subtype (22 patients). According to Motzer’s prognostic index 14 had good prognosis, 8 intermediate and 3 poor prognosis. Median time to progression was 19 weeks. Overall median survival since metastatic disease was diagnosed 8,7 months.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Bevacizumab offers, as single agent, modest activity in the metastatic renal cell carcinoma. The recently labeled use in combination with interferon as well as the newer targeted agents will improve the results of the treatment of this disease in the next future.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Referencias" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:21 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Negrier" 1 => "B. Escudier" 2 => "C. Lasset" 3 => "J.Y. Douillard" 4 => "J. Savary" 5 => "C. Chevreau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199804303381805" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "1998" "volumen" => "338" "numero" => "118" "paginaInicial" => "1272" "paginaFinal" => "1278" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9562581" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin- 2 therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G. Fyfe" 1 => "R.I. Fisher" 2 => "S.A. Rosenberg" 3 => "M. Sznol" 4 => "D.R. Parkinson" 5 => "A.C. Louie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.1995.13.3.688" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1995" "volumen" => "13" "numero" => "3" "paginaInicial" => "688" "paginaFinal" => "696" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7884429" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase III trial of high dose interleukin-2 versus subcutaneous intrleukin- 2 and interferon in patients with metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D.F. McDermott" 1 => "M.M. Regan" 2 => "J.I. Clark" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.03.206" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "volumen" => "23" "numero" => "1" "paginaInicial" => "133" "paginaFinal" => "141" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15625368" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.J. Motzer" 1 => "B.A. Murphy" 2 => "J. Bacik" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2000.18.16.2972" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2000" "volumen" => "18" "numero" => "6" "paginaInicial" => "2972" "paginaFinal" => "2980" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10944130" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase II/III trial of interferon alfa-2a with or without 13-cisretinoic acid in patients with progressive metastasic renal cell carcinoma: the European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Aass" 1 => "H.M. De Mulder" 2 => "G.H.J. Mickisch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.07.114" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "volumen" => "23" "numero" => "18" "paginaInicial" => "4172" "paginaFinal" => "4178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15961764" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Humanization of an antiVEGF monoclonal antibody for the therapy of solid tumors and other disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L.G. Presta" 1 => "H. Chen" 2 => "S.J. O´Connor" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Cancer Res" "fecha" => "1997" "volumen" => "57" "numero" => "20" "paginaInicial" => "4593" "paginaFinal" => "4599" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9377574" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A murine VEGF antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Dagnaes-Hansen" 1 => "L.M. Rasmussen" 2 => "R. Tilton" 3 => "L. Denner" 4 => "A. Flyvbjerg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Anticancer Res" "fecha" => "2003" "volumen" => "232B" "paginaInicial" => "1625" "paginaFinal" => "1630" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase Ib trial of intravenous recombinant humanized antibody to VEGF in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K. Margolin" 1 => "M.S. Gord on" 2 => "E. Holmgren" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2001.19.3.851" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2001" "volumen" => "19" "paginaInicial" => "851" "paginaFinal" => "856" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11157039" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phase I safety and pharmacokinetic study of recombinant human anti-VEGF in patients with advanced cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.S. Gordon" 1 => "K. Margolin" 2 => "M. Talpaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2001.19.3.843" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2001" "volumen" => "19" "numero" => "3" "paginaInicial" => "843" "paginaFinal" => "850" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11157038" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized trial of Bv, an anti-VEGF antibody, for metastatic renal cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.C. Yang" 1 => "L. Haworth" 2 => "R.M. Sherry" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa021491" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2003" "volumen" => "349" "numero" => "5" "paginaInicial" => "427" "paginaFinal" => "434" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12890841" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bv for patients with metastatic renal cancer: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.C. Yang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin cancer Res" "fecha" => "2004" "volumen" => "15" "numero" => "10(18 Pt 2" "paginaInicial" => "6367S" "paginaFinal" => "6370S" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, controlled, double blind phase III study (AVOREN) of Bv/IFNa- 2a vs placebo/ IFNa-2a as first line therapy in metastatic RCC" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Escudier" 1 => "P. Koralewski" 2 => "A. Pluzanska" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Prom Am Soc Clin Oncol" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "18S" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bv plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double blind fase III trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:15 [ 0 => "B. Escudier" 1 => "A. Pluzanska" 2 => "P. Koralewski" 3 => "A. Ravaud" 4 => "S. Bracarda" 5 => "C. Szcylik" 6 => "C. Chevreau" 7 => "M. Filipak" 8 => "B. Melichar" 9 => "E. Bajetta" 10 => "V. Gorbunova" 11 => "J.O. Bay" 12 => "I. Bodrogi" 13 => "A. Jagiello-Gruszfeld" 14 => "N. Moore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61904-7" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "numero" => "9605" "paginaInicial" => "2103" "paginaFinal" => "2111" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18156031" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of metastatic renal cell carcinoma with combination of Bv and erlotinib" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.D. Hainsworth" 1 => "J.A. Sosman" 2 => "D.R. Spigel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2005.01.8234" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2005" "volumen" => "23" "numero" => "31" "paginaInicial" => "7889" "paginaFinal" => "7896" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16204015" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bv with or without erlotinib in metastatic renal cell acrcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.M. Bukowski" 1 => "F. Kabbinavar" 2 => "R.A. Figlin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2006" "volumen" => "24" "paginaInicial" => "222S" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sunitinib versus IFNa in metastatic RCC" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.J. Motzer" 1 => "T.E. Hutson" 2 => "P. Tomczak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa065044" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "numero" => "2" "paginaInicial" => "115" "paginaFinal" => "124" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17215529" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sorafenib in advanced clear –cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Escudier" 1 => "T. Eisen" 2 => "W.M. Stadler" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa060655" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "numero" => "2" "paginaInicial" => "125" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17215530" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temsirolimus, IFNa or both for advanced RCC" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "G. Hudes" 1 => "M. Carducci" 2 => "P. Tomczak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa066838" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "numero" => "22" "paginaInicial" => "2271" "paginaFinal" => "2281" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17538086" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sunitinib malate for the treatment of solid tumours: a review of current clinical data" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R.J. Motzer" 1 => "S. Hoosen" 2 => "C.L. Bello" 3 => "J.G. Christensen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Expert Opin Drugs" "fecha" => "2006" "volumen" => "15" "numero" => "5" "paginaInicial" => "553" "paginaFinal" => "561" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bv in first line treatment of advanced or metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.E. Frampton" 1 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Biodrugs" "fecha" => "2008" "volumen" => "22" "numero" => "2" "paginaInicial" => "113" "paginaFinal" => "120" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18345708" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recent progress in the management of advanced renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.A. García" 1 => "B.I. Rini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2007" "volumen" => "57" "numero" => "2" "paginaInicial" => "112" "paginaFinal" => "125" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17392388" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/02104806/0000003300000002/v1_201304251922/S0210480609741130/v1_201304251922/es/main.assets" "Apartado" => array:4 [ "identificador" => "6429" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02104806/0000003300000002/v1_201304251922/S0210480609741130/v1_201304251922/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480609741130?idApp=UINPBA00004N" "pdfAlternativo" => array:1 [ 0 => array:3 [ "idioma" => "en" "documentoPdf" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/file/02104806/addon/S0210480609741130/S300/en/292v33n02a13143331pdf001_2.pdf" "portada" => "292v33n02a13143331pdf001_2.png" ] ] ]
